These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20676036)

  • 1. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets.
    Davda JP; Hansen RJ
    MAbs; 2010; 2(5):576-88. PubMed ID: 20676036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.
    Samineni D; Girish S; Li C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1557-1569. PubMed ID: 27766899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.
    Wang W; Wang X; Doddareddy R; Fink D; McIntosh T; Davis HM; Zhou H
    AAPS J; 2014 Jan; 16(1):129-39. PubMed ID: 24287601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.
    Chen X; Farrokhi V; Singh P; Ocana MF; Patel J; Lin LL; Neubert H; Brodfuehrer J
    MAbs; 2018 Jan; 10(1):62-70. PubMed ID: 29190188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody.
    Kielbasa W; Helton DL
    Cephalalgia; 2019 Sep; 39(10):1284-1297. PubMed ID: 30917684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
    Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling.
    Tiwari A; Abraham AK; Harrold JM; Zutshi A; Singh P
    AAPS J; 2017 Mar; 19(2):510-519. PubMed ID: 28004347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.
    Gobburu JV; Tenhoor C; Rogge MC; Frazier DE; Thomas D; Benjamin C; Hess DM; Jusko WJ
    J Pharmacol Exp Ther; 1998 Aug; 286(2):925-30. PubMed ID: 9694951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.
    Yuan D; Rode F; Cao Y
    Eur J Pharm Sci; 2019 Oct; 138():105032. PubMed ID: 31394258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. At the bench: the key role of PK-PD modelling in enabling the early discovery of biologic therapies.
    Penney M; Agoram B
    Br J Clin Pharmacol; 2014 May; 77(5):740-5. PubMed ID: 23962236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.
    Lee JW; Kelley M; King LE; Yang J; Salimi-Moosavi H; Tang MT; Lu JF; Kamerud J; Ahene A; Myler H; Rogers C
    AAPS J; 2011 Mar; 13(1):99-110. PubMed ID: 21240643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
    Singh AP; Shin YG; Shah DK
    Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of reversible binding by particle counting: hapten-antibody interaction as a model system.
    Sykulev YK; Sherman DA; Cohen RJ; Eisen HN
    Proc Natl Acad Sci U S A; 1992 May; 89(10):4703-7. PubMed ID: 1584807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
    de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
    Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
    Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
    J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.
    Zheng S; McIntosh T; Wang W
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S75-84. PubMed ID: 25707966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Equilibrium Models of Drug-Receptor Interactions Derived from Target-Mediated Drug Disposition.
    Peletier LA; Gabrielsson J
    AAPS J; 2018 May; 20(4):69. PubMed ID: 29761231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of in silico prediction of target suppression for antibodies against soluble targets: static versus dynamic models.
    Hijazi Y
    Eur J Clin Pharmacol; 2023 Jan; 79(1):137-147. PubMed ID: 36416938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
    Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
    Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.